Catherine Lucas

TL;DR: A newly-constructed antibody-like molecule containing the gp!20-binding domain of the receptor for human immunodeficiency virus blocks HIV-1 infection of T cells and monocytes, making it a good candidate for therapeutic use.

TL;DR: It is shown that a CD4 immunoadhesin can mediate antibody-dependent cell-mediated cytotoxicity (ADCC) towards HIV-infected cells, although, unlike natural anti-gpl20 antibodies, it does not allow ADCC towards uninfected CD4-expressing cells that have bound soluble gpl20 to the CD4 on their surface.

TL;DR: The findings suggest that although PBMC secrete latent TGF-beta 1, mechanisms that convert the latent T GF-beta complex into an active form exist in vitro and that the endogenously produced TGF -beta can regulate immune functions in an autocrine fashion.

TL;DR: The immune response elicited against the rgp120 was not effective in preventing viral infection after intravenous challenge with HIV-1 and the implications of these results on HIV- 1 vaccine development are discussed.

TL;DR: It is demonstrated that susceptibility or resistance to neutralization by antibodies to gp120 correlates with the PND sequence and suggest that the problem of antigenic variation may not be insurmountable in the development of an effective AIDS vaccine.